Real-World Outcomes of Pembrolizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
International Journal of Radiation Oncology*Biology*Physics · 2026-05 · 125 (1) · e96
DOI: 10.1016/j.ijrobp.2026.02.197 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-05. Verfasst von M. Hajiabbasi und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Hajiabbasi, M., Dharia, M., Hirofuji, E., Wong, D., & Chai-Ho, W. (2026). Real-World Outcomes of Pembrolizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics, 125(1), e96. https://doi.org/10.1016/j.ijrobp.2026.02.197
Vancouver
Hajiabbasi M, Dharia M, Hirofuji E, Wong D, Chai-Ho W. Real-World Outcomes of Pembrolizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 2026;125(1):e96. doi:10.1016/j.ijrobp.2026.02.197
BibTeX
@article{Hajiabbasi2026,
author = {Hajiabbasi, M. and Dharia, M. and Hirofuji, E. and Wong, D.J. and Chai-Ho, W.},
title = {Real-World Outcomes of Pembrolizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
volume = {125},
number = {1},
pages = {e96},
doi = {10.1016/j.ijrobp.2026.02.197}
}
EUVIMED